Search the Site


test tubes

$BDSI Strengthens Balance Sheet Ahead of Pivotal BEMA-BNX Results Late 3Q12

publication date: Jun 4, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Written by Mike Havrilla--BioDelivery Sciences (NASDAQ:BDSI) is a specialty pharmaceutical company that is focused on the development of opiate dependence and pain drugs which represent novel formulations of marketed drugs utilizing the Company’s BioErodible MucoAdhesive (BEMA) Film Technology that allows for the rapid absorption and delivery of drugs into the bloodstream from the inside of the mouth.

Sorry this page is available to subscribers only. If you're not a subscriber why not join today?

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:


If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site including:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database (updated daily)
- Members Only Live Interactive Webinars 
- Weekly Watchlist
- Email / SMS (Text Message) Alerts of critical news
- A More Detailed FDA Calendar
- Direct Email Communication
- Affiliate Program

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.